查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1598384

地中海型贫血治疗市场：按类型、适应症、最终用户划分 - 2025-2030 年全球预测

Thalassemia Treatment Market by Type (Blood Transfusion, Bone Marrow & Stem Cell Transplant, Iron Chelation), Indication Type (Alpha Thalassemia, Beta Thalassemia), End-Users - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 199 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

地中海贫血治疗市场2023年估值为63.8亿美元，预计2024年将达到70.6亿美元，复合年增长率为12.31%，到2030年将达到143.8亿美元。

地中海贫血治疗包括旨在控制这种遗传性血液疾病的医疗策略，该疾病的特征是血红蛋白生成受损并导致贫血和其他併发症。改善患者生活品质、减少对定期输血的依赖以及预防铁超载等併发症的需求推动了对地中海贫血有效治疗的需求。治疗应用包括常规输血、铁螯合疗法和新兴基因疗法，最终用途主要用于医院、专科诊所和居家医疗环境。根据市场洞察，基因治疗的进步和亚太地区及其他地区地中海贫血盛行率的增加是主要的成长要素。此外，制定个人化治疗计划和整合数位健康技术来管理患者资料和治疗方法依从性也具有巨大潜力。然而，治疗成本上升、低收入国家认知度低以及新疗法需要严格监管核准等因素对市场成长构成了挑战。创新的关键领域包括开发具有成本效益的基因编辑技术、针对更广泛的地中海贫血突变的治疗方法设计以及在治疗结果评估中使用人工智慧进行预测分析。企业应专注于建立策略伙伴关係，加强研发力度，并加速临床试验。随时了解最新的技术进步和监管变化以抓住新机会非常重要。另一方面，促进教育计划和提高公众意识有助于缓解市场限制。市场动态的动态性和简化护理的持续努力为旨在改变患者照护的创新提供了肥沃的土壤。

主要市场统计
基准年[2023] 63.8亿美元
预测年份 [2024] 70.6亿美元
预测年份 [2030] 143.8亿美元
复合年增长率（%） 12.31%

市场动态：揭示快速发展的地中海贫血治疗市场的关键市场洞察

供需的动态交互作用正在改变地中海贫血治疗市场。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，并了解消费行为及其对製造成本的影响，并更清楚地了解对采购趋势的影响。

  • 市场驱动因素
    • 地中海型贫血人口增加
    • 对地中海贫血早期诊断与治疗的认识
    • 基因组研究日益受到重视
  • 市场限制因素
    • 地中海贫血治疗相关的高成本
  • 市场机会
    • 地中海贫血新疗法的核准数量增加
    • 各国医疗基础建设支出增加
  • 市场挑战
    • 与地中海贫血治疗相关的可能併发症

波特五力：驾驭地中海型贫血治疗市场的策略工具

波特的五力框架是理解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解地中海贫血治疗市场的外部影响

外部宏观环境因素在塑造地中海贫血治疗市场的绩效动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助企业预测法规、消费者偏好和经济趋势的变化，并帮助他们做出积极主动的决策。

市场占有率分析 了解地中海贫血治疗市场的竞争状况

对地中海贫血治疗市场的详细市场占有率分析可以对供应商的表现进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵地中海贫血治疗市场供应商的绩效评估

FPNV 定位矩阵是评估地中海贫血治疗市场供应商的关键工具。此矩阵允许业务组织根据供应商的商务策略和产品满意度评估供应商，从而做出符合其目标的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析与建议绘製地中海贫血治疗市场的成功之路

地中海贫血治疗市场的策略分析对于旨在加强其在全球市场的影响力的公司至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机，并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：对当前市场环境的详细审查、主要企业的广泛资料、对其在市场中的影响力和整体影响力的评估。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 人口中地中海贫血的发生率不断增加
      • 对地中海贫血早期诊断与治疗的认识
      • 基因组研究的重要性日益增加
    • 抑制因素
      • 地中海贫血治疗相关的高费用
    • 机会
      • 核准的地中海贫血新药数量增加
      • 各国医疗基础建设支出增加
    • 任务
      • 与地中海贫血治疗相关的可能併发症
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章地中海贫血治疗市场：依类型

  • 输血
  • 骨髓和干细胞移植
  • 铁螯合
  • 鲁斯帕特西普

第七章地中海型贫血治疗市场（依适应症类型）

  • α地中海贫血
  • β地中海型贫血

第八章地中海贫血治疗市场：依最终用户分类

  • 门诊手术中心
  • 医院
  • 专科诊所

第九章美洲地中海贫血治疗市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第10章亚太地区地中海贫血治疗市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十一章欧洲、中东和非洲地中海贫血治疗市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十二章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议

公司名单

  • ApoPharma Inc.
  • Bellicum Pharmaceuticals, Inc.
  • bluebird bio, Inc.
  • Bristol-Myers Squibb Company
  • CRISPR Therapeutics AG
  • Editas Medicine Inc.
  • Errant Gene Therapeutics LLC
  • Gamida Cell Ltd.
  • GL Pharma
  • Grifols International SA
  • Ionis Pharmaceuticals, Inc.
  • La Jolla Pharmaceutical Company
  • Lonza Group AG
  • Macsen Laboratories
  • Merck & Co., Inc.
  • Novartis AG
  • Novo Nordisk A/S
  • Pfizer, Inc.
  • Pharmascience Inc.
  • Rajasthan Antibiotics Ltd
  • Sangamo Therapeutics, Inc.
  • Sanofi SA
  • Taj Pharmaceuticals Limited
  • Teva Pharmaceutical Industries Ltd.
  • Vertex Pharmaceuticals Incorporated
Product Code: MRR-C002B1C996FB

The Thalassemia Treatment Market was valued at USD 6.38 billion in 2023, expected to reach USD 7.06 billion in 2024, and is projected to grow at a CAGR of 12.31%, to USD 14.38 billion by 2030.

Thalassemia treatment encompasses medical strategies aimed at managing this inherited blood disorder characterized by faulty hemoglobin production, leading to anemia and other complications. The necessity of effective thalassemia treatments is driven by the need to improve patients' quality of life, reduce dependence on regular blood transfusions, and prevent complications like iron overload. Treatment applications include regular blood transfusions, iron chelation therapy, and emerging gene therapies, with end-use primarily among hospitals, specialty clinics, and homecare settings. Market insights reveal that advances in gene therapy and the increasing prevalence of thalassemia in regions such as Asia-Pacific are major growth factors. Furthermore, there is considerable potential in developing personalized treatment plans and integrating digital health technologies to manage patient data and adherence to treatment regimens. However, market growth is challenged by factors like the high cost of treatments, a lack of awareness in low-income countries, and the need for stringent regulatory approvals for new therapies. Key areas for innovation include developing cost-effective gene-editing technologies, crafting therapies that target a broader spectrum of thalassemia mutations, and leveraging AI for predictive analytics in treatment outcome assessments. Companies should focus on building strategic collaborations to enhance R&D efforts and accelerate clinical trials. Staying updated with the latest technological advancements and regulatory changes is crucial to capture emerging opportunities. Meanwhile, promoting educational programs and raising public awareness can aid in mitigating market limitations. The nature of the thalassemia treatment market is dynamic, with ongoing efforts to streamline therapies making it a fertile ground for innovations aimed at transformative patient care.

KEY MARKET STATISTICS
Base Year [2023] USD 6.38 billion
Estimated Year [2024] USD 7.06 billion
Forecast Year [2030] USD 14.38 billion
CAGR (%) 12.31%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Thalassemia Treatment Market

The Thalassemia Treatment Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising incidences of thalassemia disorders among population
    • Awareness related to early diagnosis and treating thalassemia
    • Growing emphasis on genomic research
  • Market Restraints
    • High cost associated with thalassemia treatments
  • Market Opportunities
    • Rising number of approvals for novel thalassemia treatments
    • Increasing healthcare infrastructure spendings across economies
  • Market Challenges
    • Possible complications associated with thalassemia therapies

Porter's Five Forces: A Strategic Tool for Navigating the Thalassemia Treatment Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Thalassemia Treatment Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Thalassemia Treatment Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Thalassemia Treatment Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Thalassemia Treatment Market

A detailed market share analysis in the Thalassemia Treatment Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Thalassemia Treatment Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Thalassemia Treatment Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Thalassemia Treatment Market

A strategic analysis of the Thalassemia Treatment Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Thalassemia Treatment Market, highlighting leading vendors and their innovative profiles. These include ApoPharma Inc., Bellicum Pharmaceuticals, Inc., bluebird bio, Inc., Bristol-Myers Squibb Company, CRISPR Therapeutics AG, Editas Medicine Inc., Errant Gene Therapeutics LLC, Gamida Cell Ltd., GL Pharma, Grifols International SA, Ionis Pharmaceuticals, Inc., La Jolla Pharmaceutical Company, Lonza Group AG, Macsen Laboratories, Merck & Co., Inc., Novartis AG, Novo Nordisk A/S, Pfizer, Inc., Pharmascience Inc., Rajasthan Antibiotics Ltd, Sangamo Therapeutics, Inc., Sanofi S.A., Taj Pharmaceuticals Limited, Teva Pharmaceutical Industries Ltd., and Vertex Pharmaceuticals Incorporated.

Market Segmentation & Coverage

This research report categorizes the Thalassemia Treatment Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Type, market is studied across Blood Transfusion, Bone Marrow & Stem Cell Transplant, Iron Chelation, and Luspatercept.
  • Based on Indication Type, market is studied across Alpha Thalassemia and Beta Thalassemia.
  • Based on End-Users, market is studied across Ambulatory Surgical Centers, Hospitals, and Specialty Clinics.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising incidences of thalassemia disorders among population
      • 5.1.1.2. Awareness related to early diagnosis and treating thalassemia
      • 5.1.1.3. Growing emphasis on genomic research
    • 5.1.2. Restraints
      • 5.1.2.1. High cost associated with thalassemia treatments
    • 5.1.3. Opportunities
      • 5.1.3.1. Rising number of approvals for novel thalassemia treatments
      • 5.1.3.2. Increasing healthcare infrastructure spendings across economies
    • 5.1.4. Challenges
      • 5.1.4.1. Possible complications associated with thalassemia therapies
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Thalassemia Treatment Market, by Type

  • 6.1. Introduction
  • 6.2. Blood Transfusion
  • 6.3. Bone Marrow & Stem Cell Transplant
  • 6.4. Iron Chelation
  • 6.5. Luspatercept

7. Thalassemia Treatment Market, by Indication Type

  • 7.1. Introduction
  • 7.2. Alpha Thalassemia
  • 7.3. Beta Thalassemia

8. Thalassemia Treatment Market, by End-Users

  • 8.1. Introduction
  • 8.2. Ambulatory Surgical Centers
  • 8.3. Hospitals
  • 8.4. Specialty Clinics

9. Americas Thalassemia Treatment Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Thalassemia Treatment Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Thalassemia Treatment Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. ApoPharma Inc.
  • 2. Bellicum Pharmaceuticals, Inc.
  • 3. bluebird bio, Inc.
  • 4. Bristol-Myers Squibb Company
  • 5. CRISPR Therapeutics AG
  • 6. Editas Medicine Inc.
  • 7. Errant Gene Therapeutics LLC
  • 8. Gamida Cell Ltd.
  • 9. GL Pharma
  • 10. Grifols International SA
  • 11. Ionis Pharmaceuticals, Inc.
  • 12. La Jolla Pharmaceutical Company
  • 13. Lonza Group AG
  • 14. Macsen Laboratories
  • 15. Merck & Co., Inc.
  • 16. Novartis AG
  • 17. Novo Nordisk A/S
  • 18. Pfizer, Inc.
  • 19. Pharmascience Inc.
  • 20. Rajasthan Antibiotics Ltd
  • 21. Sangamo Therapeutics, Inc.
  • 22. Sanofi S.A.
  • 23. Taj Pharmaceuticals Limited
  • 24. Teva Pharmaceutical Industries Ltd.
  • 25. Vertex Pharmaceuticals Incorporated

LIST OF FIGURES

  • FIGURE 1. THALASSEMIA TREATMENT MARKET RESEARCH PROCESS
  • FIGURE 2. THALASSEMIA TREATMENT MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL THALASSEMIA TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL THALASSEMIA TREATMENT MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL THALASSEMIA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL THALASSEMIA TREATMENT MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL THALASSEMIA TREATMENT MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL THALASSEMIA TREATMENT MARKET SIZE, BY INDICATION TYPE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL THALASSEMIA TREATMENT MARKET SIZE, BY INDICATION TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL THALASSEMIA TREATMENT MARKET SIZE, BY END-USERS, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL THALASSEMIA TREATMENT MARKET SIZE, BY END-USERS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS THALASSEMIA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS THALASSEMIA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES THALASSEMIA TREATMENT MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES THALASSEMIA TREATMENT MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC THALASSEMIA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC THALASSEMIA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA THALASSEMIA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA THALASSEMIA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. THALASSEMIA TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. THALASSEMIA TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. THALASSEMIA TREATMENT MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL THALASSEMIA TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL THALASSEMIA TREATMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL THALASSEMIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. THALASSEMIA TREATMENT MARKET DYNAMICS
  • TABLE 7. GLOBAL THALASSEMIA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL THALASSEMIA TREATMENT MARKET SIZE, BY BLOOD TRANSFUSION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL THALASSEMIA TREATMENT MARKET SIZE, BY BONE MARROW & STEM CELL TRANSPLANT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL THALASSEMIA TREATMENT MARKET SIZE, BY IRON CHELATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL THALASSEMIA TREATMENT MARKET SIZE, BY LUSPATERCEPT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL THALASSEMIA TREATMENT MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL THALASSEMIA TREATMENT MARKET SIZE, BY ALPHA THALASSEMIA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL THALASSEMIA TREATMENT MARKET SIZE, BY BETA THALASSEMIA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL THALASSEMIA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL THALASSEMIA TREATMENT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL THALASSEMIA TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL THALASSEMIA TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. AMERICAS THALASSEMIA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 20. AMERICAS THALASSEMIA TREATMENT MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS THALASSEMIA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS THALASSEMIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 23. ARGENTINA THALASSEMIA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 24. ARGENTINA THALASSEMIA TREATMENT MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 25. ARGENTINA THALASSEMIA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 26. BRAZIL THALASSEMIA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 27. BRAZIL THALASSEMIA TREATMENT MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 28. BRAZIL THALASSEMIA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 29. CANADA THALASSEMIA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 30. CANADA THALASSEMIA TREATMENT MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 31. CANADA THALASSEMIA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 32. MEXICO THALASSEMIA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 33. MEXICO THALASSEMIA TREATMENT MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 34. MEXICO THALASSEMIA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 35. UNITED STATES THALASSEMIA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 36. UNITED STATES THALASSEMIA TREATMENT MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 37. UNITED STATES THALASSEMIA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 38. UNITED STATES THALASSEMIA TREATMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 39. ASIA-PACIFIC THALASSEMIA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 40. ASIA-PACIFIC THALASSEMIA TREATMENT MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 41. ASIA-PACIFIC THALASSEMIA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 42. ASIA-PACIFIC THALASSEMIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 43. AUSTRALIA THALASSEMIA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 44. AUSTRALIA THALASSEMIA TREATMENT MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 45. AUSTRALIA THALASSEMIA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 46. CHINA THALASSEMIA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 47. CHINA THALASSEMIA TREATMENT MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 48. CHINA THALASSEMIA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 49. INDIA THALASSEMIA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 50. INDIA THALASSEMIA TREATMENT MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 51. INDIA THALASSEMIA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 52. INDONESIA THALASSEMIA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 53. INDONESIA THALASSEMIA TREATMENT MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 54. INDONESIA THALASSEMIA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 55. JAPAN THALASSEMIA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 56. JAPAN THALASSEMIA TREATMENT MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 57. JAPAN THALASSEMIA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 58. MALAYSIA THALASSEMIA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 59. MALAYSIA THALASSEMIA TREATMENT MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 60. MALAYSIA THALASSEMIA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 61. PHILIPPINES THALASSEMIA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 62. PHILIPPINES THALASSEMIA TREATMENT MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 63. PHILIPPINES THALASSEMIA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 64. SINGAPORE THALASSEMIA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 65. SINGAPORE THALASSEMIA TREATMENT MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 66. SINGAPORE THALASSEMIA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 67. SOUTH KOREA THALASSEMIA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 68. SOUTH KOREA THALASSEMIA TREATMENT MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 69. SOUTH KOREA THALASSEMIA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 70. TAIWAN THALASSEMIA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 71. TAIWAN THALASSEMIA TREATMENT MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 72. TAIWAN THALASSEMIA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 73. THAILAND THALASSEMIA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 74. THAILAND THALASSEMIA TREATMENT MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 75. THAILAND THALASSEMIA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 76. VIETNAM THALASSEMIA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 77. VIETNAM THALASSEMIA TREATMENT MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 78. VIETNAM THALASSEMIA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 79. EUROPE, MIDDLE EAST & AFRICA THALASSEMIA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 80. EUROPE, MIDDLE EAST & AFRICA THALASSEMIA TREATMENT MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 81. EUROPE, MIDDLE EAST & AFRICA THALASSEMIA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 82. EUROPE, MIDDLE EAST & AFRICA THALASSEMIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 83. DENMARK THALASSEMIA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 84. DENMARK THALASSEMIA TREATMENT MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 85. DENMARK THALASSEMIA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 86. EGYPT THALASSEMIA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 87. EGYPT THALASSEMIA TREATMENT MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 88. EGYPT THALASSEMIA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 89. FINLAND THALASSEMIA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 90. FINLAND THALASSEMIA TREATMENT MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 91. FINLAND THALASSEMIA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 92. FRANCE THALASSEMIA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 93. FRANCE THALASSEMIA TREATMENT MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 94. FRANCE THALASSEMIA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 95. GERMANY THALASSEMIA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 96. GERMANY THALASSEMIA TREATMENT MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 97. GERMANY THALASSEMIA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 98. ISRAEL THALASSEMIA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 99. ISRAEL THALASSEMIA TREATMENT MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 100. ISRAEL THALASSEMIA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 101. ITALY THALASSEMIA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 102. ITALY THALASSEMIA TREATMENT MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 103. ITALY THALASSEMIA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 104. NETHERLANDS THALASSEMIA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 105. NETHERLANDS THALASSEMIA TREATMENT MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 106. NETHERLANDS THALASSEMIA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 107. NIGERIA THALASSEMIA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 108. NIGERIA THALASSEMIA TREATMENT MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 109. NIGERIA THALASSEMIA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 110. NORWAY THALASSEMIA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 111. NORWAY THALASSEMIA TREATMENT MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 112. NORWAY THALASSEMIA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 113. POLAND THALASSEMIA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 114. POLAND THALASSEMIA TREATMENT MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 115. POLAND THALASSEMIA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 116. QATAR THALASSEMIA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 117. QATAR THALASSEMIA TREATMENT MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 118. QATAR THALASSEMIA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 119. RUSSIA THALASSEMIA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 120. RUSSIA THALASSEMIA TREATMENT MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 121. RUSSIA THALASSEMIA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 122. SAUDI ARABIA THALASSEMIA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 123. SAUDI ARABIA THALASSEMIA TREATMENT MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 124. SAUDI ARABIA THALASSEMIA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 125. SOUTH AFRICA THALASSEMIA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 126. SOUTH AFRICA THALASSEMIA TREATMENT MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 127. SOUTH AFRICA THALASSEMIA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 128. SPAIN THALASSEMIA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 129. SPAIN THALASSEMIA TREATMENT MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 130. SPAIN THALASSEMIA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 131. SWEDEN THALASSEMIA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 132. SWEDEN THALASSEMIA TREATMENT MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 133. SWEDEN THALASSEMIA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 134. SWITZERLAND THALASSEMIA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 135. SWITZERLAND THALASSEMIA TREATMENT MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 136. SWITZERLAND THALASSEMIA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 137. TURKEY THALASSEMIA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 138. TURKEY THALASSEMIA TREATMENT MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 139. TURKEY THALASSEMIA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 140. UNITED ARAB EMIRATES THALASSEMIA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 141. UNITED ARAB EMIRATES THALASSEMIA TREATMENT MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 142. UNITED ARAB EMIRATES THALASSEMIA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 143. UNITED KINGDOM THALASSEMIA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 144. UNITED KINGDOM THALASSEMIA TREATMENT MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 145. UNITED KINGDOM THALASSEMIA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 146. THALASSEMIA TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 147. THALASSEMIA TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023